Although IL-1 and IL-6 inhibiting agents were shown to be efficacious in AOSD [50,51], findings from clinical trials of canakinumab and tocilizumab on SJIA suggested that these therapies could not fully abrogate the risk of MAS development, even if the disease could be well controlled [52,53]. The gene discussed is IL1A; the disease is macrophage activation syndrome.